Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Abivax SA - American Depositary Shares
(NQ:
ABVX
)
130.03
+4.41 (+3.51%)
Streaming Delayed Price
Updated: 11:58 AM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abivax SA - American Depositary Shares
< Previous
1
2
Next >
Abivax Provides 2026 Corporate Outlook
January 07, 2026
From
Abivax
Via
GlobeNewswire
Abivax to be Added to Nasdaq Biotechnology Index
December 18, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
December 17, 2025
From
Abivax
Via
GlobeNewswire
Abivax Presents Third Quarter 2025 Financial Results
December 15, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
November 03, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
October 06, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
October 05, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
September 23, 2025
From
Abivax
Via
GlobeNewswire
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
September 12, 2025
From
Abivax
Via
GlobeNewswire
Abivax Presents First Half 2025 Financial Results
September 08, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Closing of $747.5 Million Public Offering
July 28, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
July 25, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
July 24, 2025
From
Abivax
Via
GlobeNewswire
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 24, 2025
From
Abivax
Via
GlobeNewswire
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 24, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Launch of Public Offering
July 23, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
July 22, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Results of its June 6, 2025 Annual General Meeting
June 11, 2025
From
Abivax
Via
GlobeNewswire
Abivax Presents First Quarter 2025 Financial Results
June 02, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
April 29, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
April 22, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
April 22, 2025
From
Abivax
Via
GlobeNewswire
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
March 26, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Full Year 2024 Financial Results
March 24, 2025
From
Abivax
Via
GlobeNewswire
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
February 21, 2025
From
Abivax
Via
GlobeNewswire
Abivax Publishes 2025 Financial Calendar
January 28, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
January 23, 2025
From
Abivax
Via
GlobeNewswire
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
January 09, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces a Change to the Composition of its Board of Directors
December 23, 2024
From
Abivax
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
